A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Solid Tumor, Adult · Colorectal Cancer · Non-Small Cell Lung · NSCLC (Non-small Cell Lung Cancer) · Cancer · Colon Cancer · Rectal Cancer · Lung Cancer · CRC · Head and Neck Squamous Cell Cancer · HNSCC · Renal Cell Carcinoma · RCC · Kidney Cancer · Triple Negative Breast Cancer · TNBC · Colorectal Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Contact: Study coordinator (Kylie Ketchum) · kylie.ketchum@bannerhealth.com
Contact: Principal Investigator (Matthew Ulrickson, MD)
UCSD Moores Cancer Center, La Jolla, California, United States
Contact: Study coordinator (Jona Plevin) · jplevin@health.ucsd.edu
Contact: Study coordinator (Rebecca Shatsky) · rshatshy@health.ucsd.edu
Contact: Principal Investigator (Rebecca Shatsky, MD)
UCLA Medical Center, Los Angeles, California, United States
Contact: Study coordinator (Lisa Del Rio) · ldelrio@mednet.ucla.edu
Contact: Principal Investigator (Deborah Wong, MD)
Mayo Clinic, Jacksonville, Florida, United States
Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015
Contact: Principal Investigator (Yanyan Lou, MD)
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Gillian Zankel) · Gillian.Zankel@moffitt.org
Contact: Principal Investigator (Kedar Kirtane, MD)
Mayo Clinic, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015
Contact: Principal Investigator (Harry E. Fuentes Bayne, MD)
Washington University, St Louis, Missouri, United States
Contact: Study coordinator (Amberly Scott) · amberly@wustl.edu
Contact: Principal Investigator (Patrick Grierson, M.D., Ph.D.)
NYU Langone Health, New York, New York, United States
Contact: Study coordinator (# Phase1Screening) · #phase1screening@nyulangone.org
Contact: Study coordinator (Salman Punekar, MD) · Salman.punekar@nyulangone.org
Contact: Principal Investigator (Salman Punekar, MD)
The Ohio State University, Columbus, Ohio, United States
Contact: Study coordinator (Cindi Jenkins) · Cynthia.Jenkins@osumc.edu
Contact: Principal Investigator (Kai He, MD, PhD)
Fred Hutch Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Shelby Colden) · scolden2@fredhutch.org
Contact: Principal Investigator (Jennifer Specht, MD)

Study leads

John Welch, MD, PhD
Study Director
A2 Biotherapeutics

View source on ClinicalTrials.gov Contact study team (email)